A randomized Phase 2 trial assessing the safety and efficacy of omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (Spectrum 6)

被引：0
|
作者：
Olander, Kenneth [1 ]
Sato, Michelle A. [2 ]
Abrams, Marc A. [3 ]
Jerkins, Gary W. [4 ]
Lu, Fenghe [5 ]
Dinh, Phillip [5 ]
Odani, Noriko [5 ,6 ]
Chabi, Almira [5 ]
Shams, Naveed Kamal [5 ,6 ]
机构：
[1] Univ Eye Specialists, Maryville, TN USA
[2] East West Eye Inst, Torrance, CA USA
[3] Abrams Eye Ctr, Cleveland, OH USA
[4] Adv Vis Res, Nashville, TN USA
[5] Santen Inc, Emeryville, CA USA
[6] Santen Pharmaceut Co Ltd, Osaka, Japan
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2020年 / 61卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4258
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
    Olander, Kenneth W.
    Sato, Michelle A.
    Abrams, Marc A.
    Jerkins, Gary W.
    Lu, Fenghe
    Dinh, Phillip
    Odani-Kawabata, Noriko
    Chabi, Almira
    Shams, Naveed K.
    JOURNAL OF GLAUCOMA, 2021, 30 (06) : 473 - 480
  • [2] Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
    Wang, Tsing Hong
    Aung, Tin
    Lu, Da-Wen
    George, Ronnie
    Senthil, Sirisha
    Lu, Fenghe
    Odani-Kawabata, Noriko
    Park, Ki Ho
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 2093 - 2106
  • [3] A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study
    Lu, Fenghe
    Aihara, Makoto
    Kawata, Hisashi
    Iwata, Akihiro
    Odani-Kawabata, Noriko
    Shams, Naveed K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [4] Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension
    Kim, Jung Soo
    Kim, Jung Lim
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2023, 64 (09): : 819 - 824
  • [5] The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension
    Stewart, WC
    Day, DG
    Stewart, JA
    Schuhr, J
    Latham, KE
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (05) : 631 - 635
  • [6] Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
    Aihara, Makoto
    Lu, Fenghe
    Kawata, Hisashi
    Iwata, Akihiro
    Odani-Kawabata, Noriko
    Shams, Naveed K.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2020, 220 : 53 - 63
  • [7] Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis
    Kuo, Hou-Ting
    Yeh, Cyuan-Yi
    Hsu, Alan Y. Y.
    Ho, Jennifer Hui-Chun
    Lin, Chun-Ju
    Tsai, Yi-Yu
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023, 39 (10) : 705 - 715
  • [8] Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
    Aihara, Makoto
    Lu, Fenghe
    Kawata, Hisashi
    Iwata, Akihiro
    Liu, Kathy
    Odani-Kawabata, Noriko
    Shams, Naveed K.
    JOURNAL OF GLAUCOMA, 2019, 28 (05) : 375 - 385
  • [9] Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study
    Makoto Aihara
    Fenghe Lu
    Hisashi Kawata
    Akihiro Iwata
    Noriko Odani-Kawabata
    Japanese Journal of Ophthalmology, 2021, 65 : 810 - 819
  • [10] Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study
    Aihara, Makoto
    Lu, Fenghe
    Kawata, Hisashi
    Iwata, Akihiro
    Odani-Kawabata, Noriko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (06) : 810 - 819
12345